“Our strong fourth quarter results cap a truly transformational year for Soleno Therapeutics (SLNO), driven by the approval and successful launch of VYKAT XR in the U.S.,” said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. “In less than nine months since launch, we have received patient start forms representing well over 10% of our addressable U.S. Prader-Willi syndrome (PWS) patient population. This reflects the significant unmet medical need that VYKAT XR can address as well as our success in communicating VYKAT XR’s value proposition to payers, providers and caregivers.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics announces publication of VYKAT XR study results in JCEM
- Optimistic Outlook for Soleno Therapeutics: Potential Synergy of Vykat in Niche Market Segments
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
- Aardvark Therapeutics initiated with a Strong Buy at Raymond James
- Soleno Therapeutics initiated with an Outperform at Wolfe Research